Bladder Cancer Clinical Trial

Mass Spectrometry in Single Bladder Cancer Cells

Summary

The study is a pilot study in the feasibility of a diagnostic technique. There is no current data on detection of cisplatin in cancer cells derived from human urine. This study will generate preliminary data so that future studies may be done with more definitive end points in mind.

View Full Description

Full Description

The aim of this study is to determine the feasibility of using a novel mass spectrometry instrument to measure the intracellular concentration of chemotherapeutic drug within an active tumor cell. If successful, this technique could be applied to dosage streamlining in patients and customization of dosage based on individual tumor characteristics. It also opens the door to research on novel chemotherapy agents or agents not typically used in a specific malignancy to determine if therapeutic levels can be obtained in tumor cells.

Personalized chemotherapy is an evolving field with the underlying goal being minimization of side effects of treatment while maximizing net patient benefit for therapy. A key difficulty in personalized chemotherapy is that the determination of therapeutic benefit comes well after the administration of treatment has been completed. For most forms of chemotherapy there does not exist a laboratory study that can determine the concentration of therapeutic agent within the tumor itself and as such, real time dose adjustments are based only on toxicity, not on tumor penetrance.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients must have a diagnosis of bladder cancer
Patients must be undergoing their first cycle of cisplatin based chemotherapy due to metastatic disease or as pre-operative treatment before cystectomy
Patients with a diagnosis of bladder cancer who will not be undergoing chemotherapy
Patients must have demonstrated positive urinary cytology prior to inclusion in the study

Exclusion Criteria:

1. Patients who do not have bladder cancer.

Study is for people with:

Bladder Cancer

Estimated Enrollment:

2

Study ID:

NCT03639090

Recruitment Status:

Completed

Sponsor:

University of Oklahoma

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Oklahoma HSC, Department of Urology
Oklahoma City Oklahoma, 73104, United States

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Estimated Enrollment:

2

Study ID:

NCT03639090

Recruitment Status:

Completed

Sponsor:


University of Oklahoma

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider